Sign in
Stories
Oncology Innovations Showcase at AACR
Share
Advanced Cancer Therapies Show Promising...
Autolus Thrives with $350M Offering and ...
BCMA-Targeted CAR-T Cell Therapy Progres...
4D Molecular Therapeutics Raises $300 Mi...
AB-2100 Phase 1/2 Trial Initiated
ADC Therapeutics Reports Financial Progr...
Overview
API
Three oncology companies, Immuneering, Prelude, and Mural Oncology, will present preclinical data at the American Association for Cancer Research annual meeting. Immuneering focuses on universal-RAS/RAF medicines, Prelude presents oral SMARCA2 degrader and CDK inhibitors, and Mural Oncology unveils IL-18 and IL-12 programs for cancer treatment.
Ask a question
How might the development of universal-RAS/RAF medicines impact the current standard of care for cancer patients?
In what ways could the advancements in engineered cytokine therapies change the landscape of cancer treatment approaches?
What synergies can be expected from combining Prelude's CDK inhibitors with other targeted therapies and how could this influence treatment strategies?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Dec 2023
Jan 2024
Feb 2024
Mar 2024
Coverage